2023 World Conference on Lung Cancer (Posters)-EP12.03. A Retrospective Analysis on the Lung Cancer Specimens for Multi-CDx System in Keio University Hospital

EP12.03. A Retrospective Analysis on the Lung Cancer Specimens for Multi-CDx System in Keio University Hospital - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the success rate of the Oncomine Dx Target Test Multi-CDx System (ODxTT) in detecting driver gene mutations in lung cancer patients. The ODxTT is a panel-based gene test using next-generation sequencing. The researchers enrolled 123 patients with non-small cell lung cancer (NSCLC) and analyzed their tumor specimens using ODxTT. They also tested the concordance rate between ODxTT and the EGFR clamp assay, which was commonly used for EGFR mutations until March 2022 in Japan.<br /><br />The results showed that ODxTT successfully analyzed 93.7% of the specimens for both DNA and RNA, while 2.4% failed for RNA, 0.8% for DNA, and 0.8% for both DNA and RNA. Driver mutations were confirmed in 58.5% of patients, with EGFR mutations detected in 30.9% of patients. The concordance rate for EGFR mutation detection between ODxTT and the EGFR clamp method was 34.4% and 36.7%, respectively. There were some cases where the results of ODxTT and the EGFR clamp assay diverged.<br /><br />The study concluded that ODxTT was able to detect driver mutations in 58.5% of cases. However, there were discrepancies between ODxTT and the EGFR clamp assay in detecting EGFR mutations. Possible reasons for unsuccessful ODxTT testing could be sample quantity or nucleic acid quality issues, or the sequencing analysis program failing to detect rare variants. Therefore, additional testing, such as cancer gene panel testing, should be performed on patients suspected of having EGFR mutations even if the ODxTT test is negative.<br /><br />This study highlights the need for accurate and reliable testing methods for identifying driver gene mutations in lung cancer patients. It also emphasizes the importance of further research and testing to ensure the effectiveness of targeted therapies in improving the prognosis of lung cancer patients.

Asset Subtitle

Ayaka Saito

Meta Tag

Speaker Ayaka Saito

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

Oncomine Dx Target Test Multi-CDx System

driver gene mutations

lung cancer patients

next-generation sequencing

non-small cell lung cancer

EGFR clamp assay

DNA and RNA analysis

EGFR mutations

concordance rate

cancer gene panel testing